|Dr. Bruce A. Goldsmith M.B.A., Ph.D.||CEO, Pres & Director||485.72k||N/A||1966|
|Dr. Stephen P. Squinto||Co-Founder, Acting Head of R&D and Director||786.99k||N/A||1956|
|Ms. Jill M. Quigley J.D.||Chief Operating Officer||756.38k||N/A||1976|
|Dr. Gary Romano M.D., Ph.D.||Chief Medical Officer||519.77k||N/A||1962|
|Dr. James M. Wilson M.D., Ph.D.||Co-Founder & Chief Scientific Advisor||N/A||N/A||1955|
|Mr. Richard S. Morris||Chief Financial Officer||N/A||N/A||1974|
|Mr. Alexandros Fotopoulos MSc, MBA||Chief Technical Officer||N/A||N/A||1969|
|Mr. Edgar B. Cale Esq., J.D.||Gen. Counsel & Company Sec.||N/A||N/A||1964|
|Robin DeRogatis||VP HR||N/A||N/A||N/A|
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Passage Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.